A5003474947- BRCA gene mutations in cancer
- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Estrogen and related hormone effects
- Genetic factors in colorectal cancer
- MicroRNA in disease regulation
- Nutrition, Genetics, and Disease
- Cancer Genomics and Diagnostics
- RNA Research and Splicing
- Cancer-related molecular mechanisms research
- Uterine Myomas and Treatments
- Cervical Cancer and HPV Research
- Endometriosis Research and Treatment
- Cancer survivorship and care
- PARP inhibition in cancer therapy
- Prenatal Screening and Diagnostics
- Global Cancer Incidence and Screening
- Menopause: Health Impacts and Treatments
- Genomic variations and chromosomal abnormalities
- Cancer Risks and Factors
- Colorectal and Anal Carcinomas
- Sexual function and dysfunction studies
- Colorectal Cancer Screening and Detection
- Cancer Immunotherapy and Biomarkers
- CRISPR and Genetic Engineering
University Medical Center Groningen
2016-2025
University of Groningen
2016-2025
Phoenix Contact (United States)
2024
Dialyse Centrum Groningen
1992-2024
The Netherlands Cancer Institute
2023
Carrier (United States)
2021
Cohort (United Kingdom)
2021
VIB-KU Leuven Center for Cancer Biology
2021
Australia New Zealand Gynaecological Oncology Group
2020
Duke University Hospital
2019
Previous studies have reported a breast cancer (BC) risk reduction of approximately 50% after risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers, but may been subject to several types bias. The purpose this nationwide cohort study was assess potential bias the estimated BC RRSO.We selected carriers from an ongoing on Hereditary Breast and Ovarian Cancer Netherlands (HEBON). First, we replicated analytical methods as previously applied four major RRSO. Cox proportional...
To compare menopause-related quality of life (QoL) after risk-reducing salpingectomy (RRS) versus salpingo-oophorectomy (RRSO) until 3 years post-surgery. A prospective study (TUBA study) with treatment allocation based on patients' preference. Data were collected pre-surgery and at months, 1 Multicentre preference trial in thirteen hospitals the Netherlands. BRCA1/2 pathogenic variant (PV) carriers aged 25-40 (BRCA1) or 25-45 (BRCA2), who premenopausal, without a future child wish current...
Abstract BACKGROUND The objective of this study was to determine whether modifications in the treatment patients with vulvar carcinoma influence rates recurrence and survival. METHODS Between 1982 1997, 253 T1 T2 invasive squamous cell vulva were treated by essentially same team gynecologic oncologists, 168 (Group I) underwent radical vulvectomy en bloc inguinofemoral lymphadenectomy. Standard therapy changed 1993, 85 II) wide local excision lymphadenectomy through separate incisions....
Recommendations for women at high risk of ovarian cancer include periodic gynecologic screening (GS) and prophylactic bilateral salpingo-oophorectomy (PBSO). The aim the current study was to determine quality-of-life (QOL) effects PBSO versus GS.Questionnaire data were obtained from 846 high-risk who had participated in this nationwide, cross-sectional, observational study. Forty-four percent undergone PBSO, 56% opted GS. Topics addressed by questionnaire included generic QOL,...
Preventive health strategies for women at increased hereditary risk of ovarian cancer include gynecologic screening (GS) and/or prophylactic oophorectomy (PBSO). Hormone replacement therapy (HRT) is often prescribed to compensate postsurgical endocrine deficiencies. This study examined the impact HRT use on levels symptoms and sexual functioning among premenopausal who have undergone PBSO. Comparisons were made with similar undergoing GS.Questionnaire data obtained from 450 premenopausal,...
Risk-reducing salpingo-oophorectomy (RRSO) around the age of 40 is currently recommended to BRCA1/2 mutation carriers. This procedure decreases elevated ovarian cancer risk by 80-96% but it initiates premature menopause as well. The latter associated with short-term and long-term morbidity, potentially affecting quality life (QoL). Based on recent insights into Fallopian tube possible site origin serous carcinomas, an alternative preventive strategy has been put forward: early risk-reducing...
Endometrial cancer (EC) risk in BReast CAncer gene 1/2 (BRCA1/2) mutation carriers is uncertain; therefore, we assessed this a large Dutch nationwide cohort study.
Women at high risk of ovarian cancer due to a genetic predisposition may opt for either surveillance or prophylactic bilateral salpingo-oophorectomy (pBSO). Main objective our study was determine the effectiveness screening in women with BRCA1/2 mutation. We evaluated 241 consecutive BRCA1 BRCA2 mutation who were enrolled program hereditary from September 1995 until May 2006 University Medical Center Groningen (UMCG), The Netherlands. included annual pelvic examination, transvaginal...
Abstract Introduction Tamoxifen is an effective treatment for breast cancer but undesirable side-effect increased risk of endometrial cancer, particularly rare tumor types associated with poor prognosis. We investigated whether tamoxifen therapy increases mortality among patients subsequently diagnosed cancer. Methods pooled case-patient data from the three largest case-control studies in relation to after (1,875 patients: Netherlands, 765; United Kingdom, 786; States, 324) and collected...
Abstract Purpose: Tumor-infiltrating lymphocytes (TIL) are associated with a better prognosis in high-grade serous ovarian cancer (HGSC). However, it is largely unknown how this prognostic benefit of TIL relates to current standard treatment surgical resection and (neo-)adjuvant chemotherapy. To address outstanding issue, we compared infiltration unique cohort patients advanced-stage HGSC primarily treated either surgery or neoadjuvant Experimental Design: Tissue microarray slides containing...
Abstract Background The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective but may be substantially biased. Prospective studies had limited power, particularly carriers. Further, previous not considered the RRSO in context natural menopause. Methods A multi-centre prospective cohort 2272 1605 was followed mean 5.4 4.9 years, respectively; 426 women developed incident...